Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

Allergan loses Latisse patent fight, jeopardizing up to $200M in sales

11.06.2014 / Fierce Pharma

As Allergan tries to fend off Valeant's hostile advances, it's been touting its sales prospects as a standalone company. But with a Tuesday court ruling invalidating patents on its eyelash growth drug Latisse, its top-line potential could shrink a little down the line.

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: